We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

1911:TSEChina Renaissance Holdings Limited Analysis

Data as of 2026-05-20 - not real-time

HK$3.49

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

China Renaissance is trading at HK$3.49, which sits below its 20‑day SMA of 3.59 and far under the 200‑day SMA of 5.21, confirming a bearish price bias. The MACD line is negative and the signal line is higher, generating a bearish MACD signal, while the 14‑day RSI at 44 suggests limited upside momentum. The stock is hovering above the calculated support of 3.20 but below the resistance near 3.84, and the 30‑day volatility of 45.7% indicates a highly erratic price environment. Despite the technical weakness, the company posted a remarkable 55.8% revenue growth year‑over‑year and trades at a forward P/E of 2.66, far cheaper than the industry average P/E of 16.48. Its price‑to‑book ratio of 0.28 and an upside potential of over 260% versus the analyst target of HK$12.77 highlight a deep valuation gap. However, the balance sheet shows a high debt‑to‑equity ratio near 6 and modest profitability margins, which temper the enthusiasm. The firm carries no dividend, and cash flow generation appears weak, adding to the risk profile. Overall, the stock is technically bearish in the short run but fundamentally attractive for longer horizons, especially if the company can convert its revenue growth into sustainable earnings.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below short‑term moving averages
  • Bearish MACD and modest RSI
  • Proximity to near‑term support level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and low forward P/E
  • Significant upside to analyst target price
  • Improving market sentiment indicated by extreme greed index

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Deep valuation discount to book and earnings
  • Potential to leverage cash reserves for strategic investments
  • Long‑run secular growth of China’s new‑economy financing demand

Key Metrics & Analysis

Financial Health

Revenue Growth55.80%
Profit Margin8.15%
P/E Ratio15.9
ROE1.30%
ROA0.91%
Debt/Equity5.99
P/B Ratio0.3
Industry P/E16.5

Technical Analysis

TrendBearish
RSI43.9
SupportHK$3.20
ResistanceHK$3.84
MA 20HK$3.59
MA 50HK$3.60
MA 200HK$5.21
MACDBearish
VolumeIncreasing
Fear & Greed Index89.21

Valuation

Target PriceHK$12.77
Upside/Downside266.04%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.90
Volatility45.69%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.